Repotrectinib increases effectiveness of MEK inhibitors in KRAS mutant cancer models.

被引：0
|
作者：
Lee, Nathan V. [1 ]
Deng, Wei [1 ]
Zhai, Dayong [1 ]
Rodon, Laura [1 ]
Parra, Ana [1 ]
Cowell, Jessica [1 ]
Banisadr, Afsheen [1 ]
Zhang, Xin [1 ]
Murray, Brion W. [1 ]
机构：
[1] Turning Point Therapeut, San Diego, CA 92121 USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1104
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Wild-type KRAS mediates growth inhibition and resistance to MEK inhibitors through dimerization with mutant KRAS in lung adenocarcinoma
    Ambrogio, C.
    Kohler, J.
    Zhou, Z.
    Wang, H.
    Paranal, R.
    Capelletti, M.
    Caffarra, C.
    Li, S.
    Lv, Q.
    Santamaria, D.
    Westover, K. D.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [22] KRAS mutation and protein levels in gastric cancer patients and response to MEK inhibitors
    Wei, J.
    Huang, Y.
    Wu, N.
    Yu, L.
    Liu, B.
    ANNALS OF ONCOLOGY, 2016, 27
  • [23] Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
    Corcoran, Ryan B.
    Cheng, Katherine A.
    Hata, Aaron N.
    Faber, Anthony C.
    Ebi, Hiromichi
    Coffee, Erin M.
    Greninger, Patricia
    Brown, Ronald D.
    Godfrey, Jason T.
    Cohoon, Travis J.
    Song, Youngchul
    Lifshits, Eugene
    Hung, Kenneth E.
    Shioda, Toshi
    Dias-Santagata, Dora
    Singh, Anurag
    Settleman, Jeffrey
    Benes, Cyril H.
    Mino-Kenudson, Mari
    Wong, Kwok-Kin
    Engelman, Jeffrey A.
    CANCER CELL, 2013, 23 (01) : 121 - 128
  • [24] PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
    Wee, Susan
    Jagani, Zainab
    Xiang, Kay Xiaoqin
    Loo, Alice
    Dorsch, Marion
    Yao, Yung-Mae
    Sellers, William R.
    Lengauer, Christoph
    Stegmeier, Frank
    CANCER RESEARCH, 2009, 69 (10) : 4286 - 4293
  • [25] Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models
    Davis, S. Lindsey
    Robertson, Kelli M.
    Pitts, Todd M.
    Tentler, John J.
    Bradshaw-Pierce, Erica L.
    Klauck, Peter J.
    Bagby, Stacey M.
    Hyatt, Stephanie L.
    Selby, Heather M.
    Spreafico, Anna
    Ecsedy, Jeffrey A.
    Arcaroli, John J.
    Messersmith, Wells A.
    Tan, Aik Choon
    Eckhardt, S. Gail
    FRONTIERS IN PHARMACOLOGY, 2015, 6
  • [26] Overcoming adaptive resistance to mutant KRAS and MEK inhibitors by co-targeting mTORC1/2 in pancreatic cancer.
    Brown, Wells
    McDonald, Paul
    Dedhar, Shoukat
    CANCER RESEARCH, 2020, 80 (22)
  • [27] Repotrectinib increases KRAS-G12C inhibitor effectiveness via simultaneous inhibition of SRC, FAK, and JAK2
    Murray, B.
    Deng, W.
    Zhai, D.
    Lee, N. V.
    Rodon, L.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S39 - S40
  • [28] Mutant KRAS inhibitors enter the scene of precision therapeutics for pancreatic cancer
    Pollin, Gareth
    Lomberk, Gwen A.
    Mathison, Angela J.
    Zimmermann, Michael T.
    Urrutia, Raul
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (04) : 1996 - 2001
  • [29] Mechanisms of Resistance to MEK Inhibitor AZ6244 in KRAS Mutant Metastatic Colorectal Cancer
    Gambino, V.
    Sun, C.
    Prahallad, A.
    Tzani, A.
    Grernrum, W.
    Mittempergher, L.
    Bernards, R.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 174 - 174
  • [30] Combination Immunotherapy with MEK Inhibitor for Treatment of Kras-Mutant Lung Cancer in Animal Model
    Lee, Jong Woo
    Zhang, Yu
    Choi, Justin
    Sharma, Roshan
    Park, Hee Sun
    Kaftan, Edward
    Papadimitrakopoulou, Vassiliki
    Herbst, Roy
    Koo, J. Peter
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1319 - S1319
12345